APO-Pemetrexed pemetrexed 500 mg (as disodium) powder for injection vial

Maa: Australia

Kieli: englanti

Lähde: Department of Health (Therapeutic Goods Administration)

Aktiivinen ainesosa:

pemetrexed disodium hemipentahydrate, Quantity: 604 mg (Equivalent: pemetrexed, Qty 500 mg)

Saatavilla:

Arrotex Pharmaceuticals Pty Ltd

INN (Kansainvälinen yleisnimi):

pemetrexed disodium hemipentahydrate

Lääkemuoto:

Injection, powder for

Koostumus:

Excipient Ingredients: sodium hydroxide; hydrochloric acid; mannitol

Antoreitti:

Intravenous Infusion

Kpl paketissa:

1

Prescription tyyppi:

(S4) Prescription Only Medicine

Käyttöaiheet:

Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell Lung Cancer (NSCLC),Pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology.,Pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Tuoteyhteenveto:

Visual Identification: White to either light yellow or green-yellow powder.; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Valtuutuksen tilan:

Registered

Valtuutus päivämäärä:

2014-09-04